Amedisys Inc. (NASDAQ:AMED) shares were down 1.5% on Tuesday . The stock traded as low as $47.01 and last traded at $47.05, with a volume of 82,763 shares. The stock had previously closed at $47.79.

Several research analysts have recently weighed in on AMED shares. Stephens started coverage on Amedisys in a report on Thursday, June 16th. They set an “equal weight” rating and a $55.00 target price on the stock. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and reduced their price target for the company from $57.00 to $55.00 in a research report on Wednesday, August 3rd. Zacks Investment Research raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $57.00 price target on the stock in a research report on Monday, May 9th. Jefferies Group reaffirmed a “buy” rating and set a $59.00 price target on shares of Amedisys in a research report on Wednesday, May 25th. Finally, Royal Bank Of Canada lifted their price target on shares of Amedisys from $41.00 to $48.00 and gave the company a “sector perform” rating in a research report on Friday, May 6th. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $51.75.

The company has a market cap of $1.56 billion and a price-to-earnings ratio of 40.66. The firm has a 50 day moving average price of $50.95 and a 200-day moving average price of $47.69.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $0.42 EPS for the quarter, meeting the consensus estimate of $0.42. The business earned $360 million during the quarter, compared to analyst estimates of $353.07 million. During the same quarter in the prior year, the company earned $0.43 earnings per share. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. On average, equities research analysts forecast that Amedisys Inc. will post $1.69 EPS for the current fiscal year.

Several hedge funds have added to or reduced their stakes in the stock. Cornerstone Capital Management Holdings LLC. raised its stake in Amedisys by 230.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 31,100 shares of the company’s stock valued at $1,223,000 after buying an additional 21,700 shares in the last quarter. Morgan Stanley raised its stake in Amedisys by 21.1% in the fourth quarter. Morgan Stanley now owns 330,210 shares of the company’s stock valued at $12,983,000 after buying an additional 57,461 shares in the last quarter. Trexquant Investment LP acquired a new stake in Amedisys during the fourth quarter valued at approximately $1,031,000. Finally, BlackRock Advisors LLC raised its stake in Amedisys by 5.1% in the fourth quarter. BlackRock Advisors LLC now owns 931,832 shares of the company’s stock valued at $36,640,000 after buying an additional 44,867 shares in the last quarter.

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.